BRAF is a serine-threonine kinase that harbors activating mutations in ~7% of human 26 malignancies and ~60% of melanomas. Despite initial clinical responses to BRAF inhibitors 27 (BRAFi), patients frequently develop drug resistance. To identify candidate therapeutic 28 targets for BRAFi-resistant melanoma, we conducted CRISPR screens in melanoma cells 29 harboring an activating BRAF mutation that had also acquired resistance to BRAFi. The 30 screens identified pathways and genes critical for BRAFi resistance in melanoma cells. To 31 investigate the mechanisms and pathways enabling resistance to BRAFi in melanomas, we 32 integrated expression data, ATAC-seq, and CRISPR screen results. We identified the JUN 33 family of transcription factors and the ETS family transcription factor ETV5 as key 34 regulators of CDK6 that enabled resistance to BRAFi in melanoma cells. Our findings reveal 35 genes whose loss of function conferred resistance to a selective BRAF inhibitor, providing 36 new insight into signaling pathways that contribute to acquired resistance in melanoma. 37 38
Introduction 41
Melanoma is an aggressive malignancy with a poor prognosis. The median survival for 42 patients with stage IV melanoma ranges from 8 to 18 months after diagnosis, depending on 43 the substage [1] . Somatic mutations in BRAF, most commonly V600E or V600K [2] , are the 44 most frequently identified cancer-causing mutations in melanoma, and recurrently appear in 45 colorectal cancer, non-small cell lung carcinoma, and many other cancers [3] . BRAF encodes 46 a protein belonging to the RAF family of serine/threonine protein kinases. This protein plays 47 demonstrated that CDK4/6 inhibitors reduced melanoma cell growth and synergized with 74 BRAF and MEK inhibitors [20] [21] [22] . These studies promoted the clinical trials of combined 75 inhibition of BRAF and CDKs. However, it is unknown whether the efficacy of combined 76 pan-CDK4/6 inhibitors with BRAFi is more through CDK4 or CDK6. Studies on the 77 mechanisms of BRAFi resistance will yield important information about the signaling 78 pathways of melanoma pathogenesis as well as how to circumvent this resistance and 79 improve efficacy of drugs. 80
In order to systematically investigate BRAFi resistance mechanism in melanoma, we 81 conducted a series of experiments in BRAF (V600E) cell lines that had obtained resistance to 82 the BRAFi PLX4032 following chronic exposure [13] . Specifically, our integrative analyses 83 of CRISPR screens, transcriptome and epigenetic profiling, revealed pathways and genes 84 associated with BRAFi resistance and tested candidate combination treatments to counter 85 BRAFi resistance. 86
Results

87
CRISPR knockout screens in a BRAF-mutant BRAFi-resistant melanoma cell line 88
To identify genes whose loss of function may counteract resistance to BRAFi, we performed 89 a CRISPR genetic screen in the human melanoma cell line M238R1 [13] . M238R1 is BRAFi-90 resistant and was derived from long-term high-dose PLX4032 treatment of parental cell line 91 M238 [13] . PLX-4032 and PLX-4720 are both BRAF inhibitors and structurally similar, but 92 PLX-4720 is reported to better inhibit BRAF V600E and to respond better in patient tumor-93 derived xenografts [23, 24] . To confirm the acquired resistance, we conducted a dose-94 response assay with PLX-4720 ( Figure S1A ). The IC50 value of the resistant line was 95 significantly higher than that of the parental line. Previous studies indicated that secondary 96 mutations in BRAF could lead to BRAFi resistance [11] . To rule out the possibility that 97 secondary mutations in BRAF led to BRAFi resistance in M238R1, we sequenced the BRAF 98 coding region. We observed the V600E mutation as expected ( Figure S1B ), but no other 99 secondary mutations in the BRAF coding region. Meanwhile, there is no BRAF amplification 100 and alternative splicing variants confer BRAFi resistance in this cell lines [25] . This indicates 101 that the drug resistance acquired by M238R1 is not due to a new genetic alteration inside the 102 BRAF coding region. 103
To identify the genes that confer resistance to BRAF inhibition, we designed a new 104 CRISPR sgRNA library targeting 6000 cancer-related genes (6K-cancer library, TableS 1) 105 based on Cosmic [26] and Oncopanel [27] (Figure 1A and Methods). For each gene, we 106 designed ten 19-bp sgRNAs against the coding region with optimized cutting efficiency and 107 minimized off-target potential using our predictive model [28] . The library contained 1466 108 sgRNAs against 147 genes essential for cell proliferation as positive controls [29] , and 795 109 non-targeting sgRNAs and 891 sgRNAs targeting AAVS1, ROSA26, and CCR5 as negative 110 controls. We performed two independent, pooled CRISPR screens by transducing a 6K-111 cancer library of lentivirus to the BRAFi-resistant cells M238R1 ( Figure 1B) . After viral 112 transduction, we treated the melanoma cells with DMSO or 1uM PLX-4720, an optimal dose 113 chosen based on our preliminary tests ( Figure S1A ). After 14 days of culturing, we harvested 114 cells from the different treated groups and extracted genomic DNA for PCR the region 115 containing sgRNAs. Then we quantified the abundance of sgRNAs through next-generation 116 sequencing (NGS) . 117 Screen data were analyzed by MAGeCK-VISPR, a statistical algorithm developed for 118 CRISPR screen analyses [30] . MAGeCK-VISPR compares the sgRNA abundance of all of 119 the sgRNAs targeting a gene across different conditions and assigns each gene a log fold-120 change "beta score (β)" of essentiality in each condition compared with Day 0 control. A 121 positive β -score indicates that silencing corresponding gene provides a growth advantage 122 under the positive selection. In contrast, the negative β -score indicates that silencing the gene 123 confers a growth or survival disadvantage under the negative selection. Replicate screen from 124 the duplicate transductions showed a good correlation at the gene level ( Figure 1C ). To assess 125 the initial quality of our screen, we check the mapping ratio, the number of missed sgRNAs, 126 and the evenness of sgRNAs ( Figure S2 ). The majority of library was maintained in the viral 127 transduction, with a small amount of missing sgRNA library constructs ( Figure S2B ). All 128 these results indicated that the screens functioned as designed. 129
Most genes that were positively or negatively selected behaved similarly in the control 130 and treatment conditions (Table S2 ). Genes positively selected in both conditions were 131 enriched for known tumor suppressors, such as NF1, NF2 as expected ( Figure S3A and 132 B).Consistent with prior work, essential genes highly overlapped between different 133 conditions strongly enriched for roles in fundamental biological processes, such as gene 134 expression, RNA processing, and translation ( Figure S3C and D). These results are consistent 135 with a properly functioning CRISPR screen. 136
Identification of genes essential specifically for growth of cells resistant to PLX-4720 137
To explore which genes might play a role in the BRAFi-resistance, we performed further 138 analysis of CRISPR screen data using MAGeCKFlute [29] . MAGeCKFlute facilities 139 comparison of β score between different conditions. We adopted a "quantile matching" 140 approach to robustly estimate σ , which is the standard deviation of the differential β score 141 ( Figure S4A ). We identified genes whose β score decreased in the presence of BRAFi 142 treatment compared to DMSO treatment ( Figure S4B and Table S2 ). Then, we selected 322 143 candidates whose disruption does not normally affect survival but becomes lethal in the drug 144 treatment condition. We ranked the identified hits by the change of the β score ( Figure 1D ). 145
Here ,we labeled the top 10 genes, such as SOS1, PURA, HRAS, SAFB, CRKL, ETV5, CDK6, 146 DYNCH1, H2AFX and MAZ. Among these 322 candidate genes, HRAS, SRC, SOS1, EGFR, 147 and RAF1 were previously reported to be involved in BRAFi resistance [31, 32] (Figure 1E ). 148
To further understand the pathways conferring BRAFi-resistance, we performed 149 GO/GSEA/pathway analyses with the 322 candidate genes ( Figure 1F ). Among the network 150 of genes whose β score decreased after drug treatment, we found that the ERBB2 signaling 151 pathway, RAS pathway, ERK pathway, MAPK pathway, and EGFR signaling pathway are 152 highly enriched. These results are consistent with previous studies [13, 31, 33, 34] . Besides 153 these known pathways, cell-cycle genes, and G1/ transition S of mitotic cell cycle were the 154 most enriched newly discovered class ( Figure 1F ), represented by CDK6, CCND1, PSMB1, 155 and RRM2. 156
CDK6 confer resistance to BRAF inhibition in melanoma cells 157
We next sought to determine whether any genes whose upregulation confers resistance to 158 BRAF inhibition in melanoma cells. To assess this, we analyzed previously generated gene 159 expression profiles in parental versus resistant cells treated with PLX4720 or treated with 160 DMSO [13]. In the sensitive cells, PLX4720 induced widespread changes in gene expression 161 ( Figure S5A ). Our analysis showed that the MAPK signaling pathway and the PI3K-AKT 162 pathway were down-regulated, consistent with previous studies [13, 14] ( Figure S5B ). The 163 resistant line exhibited fewer differentially expressed genes upon PLX4720 treatment ( Figure  164 S5C). We next analyzed the genes that were differentially expressed between the resistant 165 line and the parental line upon PLX4720 treatment. Under BRAFi treatment, there are 1,374 166 up-regulated and 1,574 down-regulated genes in resistant cells relative to sensitive cells 167 ( Figure 2A and Table S3 ). Our re-analyses confirmed the previously reported overexpression 168 of KIT, MET, EGFR, and PDGFRB in M238R1 relative to the parental line [13] . In addition, 169
we found that the cell cycle genes CDK6, CCND1, and transcription factor (TF) JUN were 170 up-regulated in resistant cells compare to the parental cells ( Figure 2A ). 171
We hypothesized that genes with elevated expression in BRAFi resistant cells, as well as 172 the loss of function restored the drug sensitivity, may be responsible for the resistance 173 phenotype. We next integrated the expression results and CRISPR screen results to identify the dysregulated genes related with BRAFi resistance. Within the 322 genes whose depletion 175 sensitize cells to BRAFi, there are 12 genes, including CDK6, specifically over-expressed in 176
BRAFi-resistant cells ( Figure 2B ). This suggests that 21 genes might be associated with the 177 resistance to BRAFi and mediate cell proliferation in the resistance line. 178
To explore the potential druggable targets for the BRAFi-resistant cells, we further 179 filtered the candidate gene with DGIdb [35] . DGIdb is a carefully curated database of 180 published information on drug-gene interactions and the druggable genome. It offers user-181 friendly functions for browsing, searching, and filtering. DGIdb identified CDK6 as a 182 potential druggable target with the FDA approved drugs for BRAFi-resistant cells.CDK6 is 183 regulated by Cyclin D proteins and Cyclin-dependent kinase inhibitor proteins. Altered 184 expression of these cell cycle genes has been observed in multiple human cancers [36, 37] . 185 CDK6-targeting sgRNAs were markedly depleted in the PLX-4720 condition compared to 186 the DMSO condition ( Figure S6A ), suggesting that loss-of-function of CDK6 can cause cells 187 sensitive to PLX-4720. To validate this result from the initial screen, we used five 188 independent sgRNAs to knockout CDK6 in the M238R1 cell line ( Figure 2C ). Consistent 189 with our screen data, CDK6 knockout cells showed increased sensitivity to PLX-4720 in 190 long-term colony-formation viability assays ( Figure 2D ). Most tumors including melanoma 191 have an abnormal G1-to-S transition, mainly due to dysregulation of CDKs activities [38, 39] . 192
We wondered if the increased essentiality we observed for CDK6 was a general property of 193 CDKs or was specific to CDK6. We specifically evaluated the changes in essentiality of the 194 other CDKs ( Figure S6B treated with PLX-4720. On average, we sequenced each sample at ~50 million PE150 204 fragments and observed ~89% uniquely mapped ratio (Table S4 ). We evaluated the quality of 205 deep-sequencing data in diverse sections, such as including the uniquely mapped reads, PCR 206 bottleneck coefficient (PBC) score, High quality peaks number, fraction of non-mitochondrial 207 reads in peak region (FRiP), peaks overlapping with union of DNaseI peaks (DHS) (Figure  208 S7). The ATAC-seq profiles showed the high-quality features according the criteria defined 209 by Cistrome database, which is a data portal for more than 8,000 ChIP-Seq and chromatin 210 accessibility data in human and mouse [41] . 211
In total, 113,725 high-confidence open chromatin regions (or peaks) were identified in the 212 parental line, and 96,038 peaks were identified in resistant line. Of the distinct peaks, we 213 identified the peaks more accessible in parental cells (M238-specific peaks), and the peaks 214 more accessible in resistant cells (M238R1-specific peaks) ( Figure 3A and Table S5 ). Figure 3B ). To investigate the relationship between activated TFs and their target genes, we 219 integrated the ATAC-seq results with gene expression results. We identified the genes that 220 were up-regulated in M238R1 treated with BRAFi and also associated with M238R1-221 sepecific peaks. These genes are related to EGFR signaling, epithelial cell proliferation, skin 222 development, and angiogenesis ( Figure 3C ), which are fundamental biological processes of 223 melanoma development. Therefore, analysis of the ATAC-seq data in conjunction with the 224 expression data revealed a set of TFs and their target genes that are associated with BRAFi 225 resistance. 226
Identification of the JUN family and ETV5 as key regulators of CDK6 227
To identify the transcription factors that regulate CDK6 expression, we used the Cistrome 228
ToolKit To assess other genes that might act with JUN to regulate CDK6, we examined the set of 241 genes that physically interact with the JUN protein according to the STRING database and 242 genes whose essentiality increased after BRAFi treatment. We identified ETV5 as being in 243 both of these gene sets ( Figure 4C ). ETV5 is a member of the ETS family of transcription 244 factors which controls cell cycle gene expression and contributes to tumorigenicity [48] . 245
Increased expression of ETV transcription factors modulates the response to MEK inhibition 246
[49]. Motif enrichment analysis of ChIP-seq data can help us identify transcription factors 247 that cooperate with ETV5. According to the Cistrome Data Browser [41], the JUN motif is 248 enriched ETV5 ChIP-seq peaks, suggesting JUN family might be a co-factor of ETV5 249 ( Figure 4D ). Consistent with the hypothesis that ETV5, JUN, and JUNB directly regulate 250 CDK6, these TFs have strong binding around the CDK6 gene ( Figure S8C ). We found that 251 ETV5 deletion reduced sensitivity to BRAF inhibition by PLX-4720 in melanoma cells and 252 ETV5 was the top hit of the genes that were more essential in the BRAFi treatment condition 253 ( Figure 1D ). Similar to CDK6, the normalized sgRNA read counts of ETV5 continually 254 decrease in the DMSO treatment or PLX-4720 treatment ( Figure S8A and B). Finally, we 255 experimentally validated that the depletion of ETV5 decreases the expression of CDK6 256 ( Figure 4E ). These observations suggest that CDK6 mediate resistance to BRAF inhibition by 257 the collaborative regulation of TFs JUN and ETV5, which increased expression of CDK6 and 258 promote the cell proliferation. 259
Dual inhibition of BRAF and CDK6 in BRAFi-resistant cell lines 260
Palbociclib (IBRANCE, Pfizer Inc.) is an inhibitor of CDK4 and CDK6 approved by the 261 FDA in many cancer types [50] . CDK inhibitor, and combination of BRAFi or MEKi or a 262 CDK4 inhibitor significantly suppresses growth and enhances apoptosis in melanoma cells 263 [21, 22] .However, the efficacy combination therapy of pan-CDK4/6 inhibitors with BRAFi is 264 more through CDK4 or CDK6,whch remains poorly understood. Here, we first examined the 265 changes in essentiality of the other CDKs ( Figure S6B ). Among all CDKs, only CDK6 is 266 more highly expressed in the resistant cell line compared to the sensitive cell line and 267 becomes more essential in the presence of BRAFi. Further we assessed the synergy between 268
CDK6 and BRAF inhibition on BRAFi resistant cells. To verify the activity of Palbociclib, 269
we showed that 1µM of palbociclib effectively reduced the phosphorylation of CDK6's 270 substrate RB1 ( Figure 5A ). We then treated BRAFi resistant cells with palbociclib and/or 271 PLX-4720 and observed that inhibition of CDK6 sensitized cells to PLX-4720 treatment in a 272 clonogenic assay ( Figure 5B ). This treatment combination is highly synergistic across a broad 273 range of concentrations according to the Bliss independence model, especially in the resistant 274 lines ( Figure 5C , 5D and Figure S9 ). These results support the potential of CDK6 and BRAF 275 dual inhibition as a therapeutic strategy to overcome BRAFi resistance in our resistant model. 276
CDK6 expression is negatively associated with overall survival in BRAF-mutant 277 melanomas treated with BRAFi 278
To determine whether the expression of any validated BRAFi-resistant genes we identified 279 correlated with resistance to BRAF inhibitor therapy in melanomas, we analyzed expression 280 data from two independent cohorts [33, 51] . In cohort one [51], 18 patients were treated 281 either with BRAFi alone (12 patients) or dual BRAFi and MEKi therapies (6 patients). RNA-282 seq data on serial tumor biopsies of matched pre-treatment and relapsed tumors were 283 available. In cohort two, 22 patients with advanced melanoma were treated with BRAFi (7 284 patients) or BRAFi plus MEKi (15 patients) [33] . RNA-seq data on pre-treatment, on-285 treatment, or relapsed tumors were available, although they were not paired. These samples 286 were classified into 3 groups: 14 pre-treatment specimens, 12 on-treatment specimens, and 12 287 clinical progression specimens. Of the 21 over-expressed genes also identified in our 288 CRISPR screen, CDK6, CCND1, and ETV5 were more highly expressed in the tumors that 289 have relapsed after BRAFi treatment relative to the on-treatment groups ( Figure 6A ). 290
We next investigated whether CDK6 upregulation might be associated with clinical 291 resistance in some cases. To facilitate this, we generated a 10-gene CDK6 expression 292 "signature" (Table S6) Several genome-wide CRISPR pooled screens have uncovered mediators of drug 325 resistance [53, 54] . In this study, we used CRISPR screens to systematically characterize 326 resistance to BRAF inhibitor PLX-4720 in melanoma. Our screen identified both previously 327 known and novel resistance genes to BRAF inhibition. Previously reported genes were 328 identified by our screen, including CCND1, RAF1, EGFR, and SRC [19, 31, 34 ]. Among the 329 network of genes whose β score decreased after drug treatment, we also found that the 330 Figure S5B ). Thus, our study demonstrates the feasibility 361 of genome-wide pooled CRISPR-Cas9 knockout screens of resistant cells for uncovering 362 genetic vulnerabilities that may be amenable to therapeutic targeting. 363
We found that CDK6 deletion reduced resistance to BRAFi treatment in vitro and 364 demonstrated that the CDK6 inhibitor palbociclib act synergistically with BRAFi to halt cell 365 growth in BRAFi-resistant cell lines. To further demonstrate the potential combination 366 therapy, we tried to generate M238R1 xenografts. However, this effort failed, consistent 367 reports from the lab that derived the resistant cell line (Lo Lab, personal communication). 368
Additional evidence that CDK6, ETV5 and JUN may confer resistance to BRAF inhibition in 369 cancer emerged from our analysis of two independent melanoma cohorts. This analysis 370 revealed high levels of CDK6 and ETV5 in tumors that acquire resistance to BRAFi 371 treatment, thereby providing genetic evidence that these signaling pathways may dysregulate 372 upon BRAF inhibition. A high CDK6 signature score is associated with the poor progression-373 free survival of melanoma patients in both clinical cohorts. These observations suggest that 374 elevated global expressions of CDK6, JUN and ETV5 modulate the response to BRAF 375 inhibitor treatment. Our study strengthens this link by demonstrating that a combination of 376 CDK6 inhibitor and BRAF inhibitor can overcome BRAFi resistance. 377
In conclusion, this study shows that there was a significant increase of CDK6 expression 378 in the BRAFi-resistant cell lines and progressive tumors. Through the loss-of-function 379 screens, epigenetic profiles, and gene expression analysis, we have identified a network that 380 includes CDK6, ETV5, and JUN as the potential mechanism for BRAFi-resistant melanoma 381 cells. Our findings offer new insights into resistance to BRAF inhibitors and support clinical 382 studies of combined BRAF and CDK6 inhibition in a subset of activating BRAF mutations 383 subject to relapse through acquired resistance. 384 packaging virus, HEK293T cells were grown in DMEM with 10% FBS, glutamine and 1% 393 penicillin/streptomycin. Stocks of BRAF inhibitor PLX4720 (Catalog No. S1152) and CDK6 394 inhibitor palbociclib Isethionate (PD0332991, Catalog No. S1579) were purchased from 395 Selleck Chemicals. 396
Materials and methods
Library design 397
To design a smaller-scale CRISPR/Cas9 knockout screen library focusing on cancer-related 398 genes, we selected 6000 genes based on reported relevancies with cancers using multiple 399 sources, including Cosmic and Oncopanel (Table S1 ). For each gene, we designed ten 19nt 400 single-guide RNA (sgRNA) against its coding region with optimized cutting efficiency and 401 minimized off-target potentials. We used sequence features of the spacers to calculate the 402 cutting efficiency score for each sgRNA using our predictive model. We used BOWTIE to 403 map all candidate sgRNAs to hg38 reference genome, and chose those with fewest potential 404 off-targets. We selected the 10 best sgRNAs for each gene based on the considerations above. 405
The library also contains both positive controls and two types of negative controls: non-406 targeting controls and non-essential-region targeting sgRNAs. 407 a) Positive controls: we included 1466 sgRNAs targeting 147 positive control genes, which 408 are significantly negatively selected in multiple screen conditions. 409 b) Non-targeting negative controls: 795 sgRNAs with sequences not found in genome. c) Non-essential-region-targeting negative controls: 1891 sgRNAs targeting AAVS1, 411 ROSA26, and CCR5, which have been reported as safe-harbor regions where knock-in 412 leads to few detectable phenotypic and genotypic changes. 413
Cloning of individual sgRNAs and sgRNA libraries 414
For the 6K-cancer library, we used the lentiCRISPR v2 vector (also available at Addgene, 415 plasmid #52961) as backbone [58] . We designed ten sgRNAs per gene to target ~6,000 genes 416 and added non-targeting sgRNAs as controls (Table S1) Table S7 . 421
Virus production and infection 422
Lentivirus was generated in HEK293T cells by transfecting cells with packaging DNA plus 423 lenti-CRISPR vectors. For each library to be transfected, we plated HEK293T cells in 25ml 424 of media in a 15 cm tissue culture plate. Typically, 20 μ g vector DNA, 15 ug psPAX2 425 packaging plasmid, 6 ug pMD2.G envelope plasmid and 200 ul transfection reagent X-426 tremeGENE were used; DNA and transfection reagent X-tremeGENE were pre-diluted in 3 427 ml serum-free OPTI-MEM individually and then mixed. After 15 min of incubation, the 428 DNA and transfection reagent mixtures were added to HEK293T cells seeded in the dish. 429
After 8-12 h, the media was changed to 25 ml DMEM + 10% FBS+ 1%BSA. Viral 430 supernatant was collected two and three days after transfection, filtered through 0.45-μm 431 membranes, and added to target cells in the presence of polybrene (8 μ g/ml, Millipore). After 432 48h, puromycin (2 μ g/ml) was used to treat cells for two days for selection, which eliminated 433 all cells in an uninfected control group. 434
Pooled CRISPR screen 435
For the pooled CRISPR screen, a total of 1.2x10 8 cells were infected with the pooled 436 lentiviral library at a MOI of 0.3. After puromycin selection, the surviving cells were divided 437 into three groups (day0 control, vehicle, and drug treatment). For the drug treatment group, 438 the cells were treated with 1uM PLX4720. The cells were cultured in medium for ten 439 doubling times and split every 2-3 days before genomic DNA extraction and library 440 amplification. 441
Amplification and sequencing of sgRNAs from cells 442
After cell harvest, DNA was purified using QIAGEN DNeasy Blood & Tissue Kit according 443 to the manufacturer's instruction. PCR was performed as previously described [58] , and the 444 PCR products were sequenced on a HiSeq 2500. Each library was sequenced at 30~40 445 million reads to achieve ~300X average coverage over the CRISPR library. The day 0 sample 446 library of each screen could serve as controls to identify positively or negatively selected 447 genes or pathways. 448
CRISPR screen analysis 449
The CRISPR/Cas9 screening data were analyzed using MAGeCK and MAGeCK-VISPR 450 algorithms [30] . MAGeCK-VISPR uses a metric, "β score", to measure gene selections. The 451 definition of the β score is similar to the term of 'log Fold Change' in differential expression 452 analysis, and β >0 (or <0) means the corresponding gene is positively (or negatively) selected, 453 respectively. We considered a β score of >0.5 or <-0.5 as significant. MAGeCK-VISPR 454 models the gRNA read counts as a negative binomial variable, whose mean value is 455 
ATAC-seq 469
ATAC-seq libraries were prepared according to the previously described Omni-ATAC 470 protocol [60] . After the cells counting, 50,000 cells were resuspended in 1 ml of cold ATAC-471 seq resuspension buffer (RSB; 10 mM Tris-HCl pH 7.4, 10 mM NaCl, and 3 mM MgCl2 in 472 water). Cells were pelleted by centrifugation at 500 r.c.f at 4 ˚C for 5 min in a pre-chilled 473 (4 °C) centrifuge. After centrifugation, supernatant was carefully aspirated to leave the cell 474 pellet undisturbed. Cell pellets were then resuspended in 50 μ l of ATAC-seq resuspension 475 buffer containing 0.1% NP40, 0.1% Tween-20, and 0.01% digitonin by pipetting up and 476 down three times. This cell lysis reaction was incubated on ice for 3 min. After lysis, 1 ml of 477 ATAC-seq RSB containing 0.1% Tween-20 (without NP40 or digitonin) was added, and the tubes were inverted 3 times to mix. Nuclei were then centrifuged for 10 min at 500 r.c.f. 4 °C 479 centrifuge. Nuclei were resuspended in 50 μ l of transposition mix (25 μ l 2× TD buffer, 2.5 μ l 480 transposase (100 nM final), 16.5 μ l PBS, 0.5 μ l 1% digitonin, 0.5 μ l 10% Tween-20, and 5 μ l 481 nuclease-free water) by pipetting up and down six times. Transposition reactions were 482 incubated at 37 °C for 30 min in an Eppendorf ThermoMixer with shaking at 1,000 r.p.m. 483
Tagmented DNA was purified using the MinElute Reaction Cleanup Kit (Qiagen, 28204) . 484
The ATAC-seq library preparation was performed as described previously [40] . Then, the 485 concentration of the library was determined using Qubit 3.0 (Life Technologies) and the size 486 distribution was assessed using Agilent 4200 TapeStation system. Libraries were paired-end 487 sequenced (35bp) on an Illumina NextSeq 500. 488
ATAC-seq data analysis 489
Quality control, reads alignment, peak calling were performed by ChiLin [61]. The M238 and 490 M238R peaks were further merged (using the BEDtools [62] 'merge' function). BEDtools 491 'coverage' was used to create an input matrix used for detecting differentially accessible, 492 peaks. We assessed the significant change of chromatin accessibility between different 493 groups using the DESeq2 R package [63] . The total count of qualified fragments in each 494 sample was used as the library size. It was defined as significantly changed if the peak 495 showed log2 fold change > 1 and adjust P-value < 0.05. The HOMER tool suite was used for 496 TF motif discovery, by analyzing differential motif enrichment in M238R specific element 497 datasets against all elements (peaks) background. Regulatory potential (RP) scores derived 498 with the BETA algorithm are used to estimate how likely a factor regulates genes [64] . 499
ChIP-seq data mining in Cistrome Data Browser 500
We used the Cistrome Data Browser Toolkit function to investigate the transcriptional factors 501 which could regulate CDK6 [41]. This function would return a list of the transcription factors 502 that are most likely to regulate of CDK6. To identify the potential cooperative factors of 503 ETV5, we used the analysis results from the Cistrome Data Browser [41]. ETV5 ChIP-seq 504 data with the high-quality (Cistrome Data Browser ID: 42714) were used to explore the 505 potential cooperative factors of ETV5. In the "QC Motifs" panel, it shows the significantly 506 enriched motifs of other factors in the ETV5 ChIP-seq peaks. 507
Western Blot analysis 508
For western blotting, cells were lysed in RIPA buffer (Santa Cruz Biotechnology) 509 supplemented with phosphatase and protease inhibitor cocktail. Protein concentrations were 510 measured with Thermo Fisher Scientific Bradford Assay (# PI23236). ETV5 Antibody 511 (catalog: ab102010) was purchased from Abcam, and CDK6 Antibody (catalog: sc-7961) was 512 purchased from Santa Cruz Biotechnology. ERK2 Antibody (Santa Cruz Biotechnology, sc-513 1647) GAPDH (Sigma, G9545), and VINCULIN (Santa Cruz Biotechnology, sc-73614) were 514 used as a loading control. Goat anti-rabbit and Goat anti-mouse secondary antibodies were 515 obtained from LI-COR Biosciences. The fluorescent signals were developed with Odyssey 516 CLX Imaging System (LI-COR Biosciences). 517
Cell proliferation and colony formation assays 518
Response to a single agent-or combination-treatment was assessed by either the CellTiter 96 519 cell proliferation assay from Promega. Cells were seeded in 96-well plates (2,000 cells per 520 well), and cultured 18 to 24 hours before compound addition. The cells were treated with 521 various concentrations of BRAFi or/and CDK6i for 72 hr and then incubated with CellTiter 522 96 AQueous One Solution Reagent for 1-4 hr per manufacturer's protocol before recording 523 the absorbance at 490 nm on SpectraMax M2 (Molecular Devices). All experiments were 524 performed in triplicate. For colony formation assays, cells were seeded in a 24-well plate at a 525 density of 300, allowed to attach for 24 hours at 37°C, and then treated with PLX4720. The 526 cells were maintained at 37°C for two weeks. Colonies of cells were then fixed with cold 527 methanol for 25 minutes and stained with 1% crystal violet. 528
Drug synergy analysis 529
Drug synergy was calculated based on the Bliss independence model using the 530 SynergyFinder R package [65] .The Synergy score based on Bliss model. 531 the difference between treatment and control beta scores. Red dots are genes whose beta 722 score increased after treatment. Blue dots are genes whose beta score decreased after 723 treatment. Gray dots are genes whose beta score did not change significantly between 724 different conditions. E. Beta scores of SOS1, RAF1, HRAS, EGFR, and SRC in the 725 PLX4720 condition and DMSO condition. A. Density plot of differential beta scores compared PLX4720 treatment condition with 794 DMSO treatment condition. Delta is used to measure the change of beta score in the two 795 conditions. Delta was calculated by the formula shown in the right panel. If the genes' 796 differential beta scores are bigger than delta (the red line), theses genes' essentiality 797 decreased after PLX4720 treatment. Delta is 0.134 in our screen data. Genes' differential beta 798 scores are smaller than minus delta (the blue line), which indicate theses genes' essentiality 799 increased after PLX4720 treatment. B. The beta score of M238R1 cell line with the treatment 800 of DMSO and PLX4720. The two diagonal lines indicate +/-1 delta of the difference between 801 treatment and control beta scores. Red dots are genes whose beta score increased after 802 treatment. Blue dots are genes whose beta score decreased after treatment. 803 
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